Day 1

Introduction of the Guideline for Pharmacological Therapy of SchizophreniaHiroyuki Uchida, Japan   Implementing Evidence-Based Practices for People with Schizophrenia in JapanKenji Sakuma, Japan   Pharmacological Treatment of Relapse/Recurrence in Patients with SchizophreniaHikaru Hori, Japan   Maintenance Treatment of SchizophreniaHiroyoshi Takeuchi, Japan   Treatment Resistance SchizophreniaRyota Hashimoto, Japan      Chairperson: Ryoto Hashimoto This symposium is …

Optimizing Treatment for Patients with SchizophreniaAhmad Hatim B Sulaiman, Malaysia Effect of Adjuvant Vitamin C on Brain-Derived Neurotrophic Factor (BDNF) Levels and Improvement of Negative Symptoms in Schizophrenic PatientsKristian Liaury, Indonesia Recent Trend in Neuropsychopharmacology in JapanNorio Yasui-Furukori, Japan Profiles of antipsychotic use among schizophrenia patients in Indonesia: Results from the REAP StudyAndi Tanra, Indonesia …

The impact of COVID-19 on the treatment model of mental disorders  Li Yi, China Mental health outcomes among patients exposed to COVID-19 : Experience from Fangcang shelter hospitalGuangyin Zhang, China Lessons Learned from Covid-19 Pandemic: Indonesia’s PerspectiveAndi J Tanra, Indonesia Health Care Worker Wellness During Covid-19: The New Normal in SingaporeTji Tijan Chee, Singapore The …

Differential roles of 5-HT3 and 5-HT7 receptors in acute pruriceptive processing in miceYu Miyahara, Japan A gene genetically associated with herpes zoster or post-herpetic neuralgia has impacts on varicella-zoster virus-mediated fusogenic activitySeii Ohka, Japan Association between postoperative analgesia after major abdominal surgery and a single nucleotide polymorphism rs12496846 in the C3orf20 gene region, identified to …

Chairperson:  Roger Ho, Singapore This session is made possible by kind support from Servier.

Asian Perspective on Challenges in Managing Bipolar I Disorder (Bipolar Depression)Ya Mei Bai, Taiwan Navigating the Lows: Current Evidences on Pharmacological Treatment for Bipolar I Disorder (Bipolar Depression)Leslie Citrome, USA Chairpersons:Ya Mei Bai, TaiwanLeslie Citrome, USA Provision of the virtual auditorium venue for this session is made possible by a kind donation from Sumitomo Pharmaceuticals …

Novels treatments in Huntington’s disease and frontotemporal dementia – an Australian perspectiveDennis Velakoulis, Australia Neuropsychiatric Aspects of Niemann Pick Type C Disease in AdultsMark Walterfang, Australia Advances in pharmacological treatments of Alzheimer’s Dementia and Fronto-Temporal DementiaSimon Ducharme, Canada Chairperson:  Cyrus Ho, Singapore

Multiple modes of stress-induced inflammation in the brain and peripheryTomoyuki Furuyashiki, Japan Thalamic microglial activation and cognitive impairmentShin-ichi Kano, USA Interaction between microglia and neurons: role in stress sensitivity and depression treatmentLaura Maggi, Italy Epigenetics, neuroinflammation and aging: genome-wide DNA methylation of deliriumGen Shinozaki, USA Human blood-induced microglia-like (iMG) cells as a reverse translational research …

“Treatment resistance” is a definition that does not belong to the classification system, because it depends on the availability of suitable therapies at a given point in history. However, it has regulatory implications, and it may be useful for clinical practice. Treatment resistance is quite well defined in the field of depression, but not so …

Polypharmacy in Bipolar disorder: Findings from REAP Bipolar Disorder studyVie Cheong Thong, Malaysia Clinical use of mood stabilizers in REAP Study – Focus on clinical symptoms of bipolar disorderIsa Multazam Noor, Indonesia Clinical use of mood stabilizers in Asian patients: summary from REAP-BD and MS studiesPornjira Pariwatcharakul, Thailand Research on Asian Psychotropic Prescription Patterns on …